TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00930605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen alternate with ESHAP regimen
Description: CHOP alternate with ESHAP is given every 21 days for a total of 6 course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
Study: NCT01695850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MZRW
Description: Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: Patients are instructed to take 2 tablets at the bedtime for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
Study: NCT00150670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 and cisplatin
Description: TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TS-1
Description: TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
Study: NCT03117166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
Study: NCT04191291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lunch period length
Description: We are randomly allocating a 10 minute or 20 period of seated lunch time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lunch period length
Description: We are randomly allocating a 10 minute or 20 period of seated lunch time.
Study: NCT06287008

Intervention type: PROCEDURE
Intervention: robot-assisted kidney transplantation
Description: The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
Study: NCT04258163

Intervention type: DRUG
Intervention: Capecitabine
Description: 1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days

Intervention type: DRUG
Intervention: Liposomal doxorubicin
Description: 50 mg/m 2 IV day 1, cycled every 28 days

Intervention type: DRUG
Intervention: Gemcitabine
Description: 800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days

Intervention type: DRUG
Intervention: Fulvestrant
Description: 500mg IH Days 0, 14, 28, then every 28 days

Intervention type: DRUG
Intervention: Anastrozole
Description: 1mg PO qd

Intervention type: DRUG
Intervention: Letrozole
Description: 2.5mg PO qd
Study: NCT04237324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment one side BLE by NAFL
Description: One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment another side BLE by FMR
Description: One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
Study: NCT03863236

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: regular diet
Description: The control group (group 1) will continue their regular diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional support Resource 2.5
Description: The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
Study: NCT03052842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Strip
Description: Antimicrobial Peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Strip
Description: Antimicrobial Peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Strip
Description: Antimicrobial Peptide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Strip
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Strip
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Strip
Description: Placebo
Study: NCT00470652

Intervention type: DEVICE
Intervention: computer-assisted decision support
Description: at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was \>4/10. After a 10-day test period, the post-intervention data collection started.

Intervention type: DEVICE
Intervention: computer-assisted decision support
Description: at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was \>4/10. After a 10-day test period, the post-intervention data collection started.
Study: NCT02638896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept (Half-Dose)
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept (Full-Dose)
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
Study: NCT01456013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard of care for patients at risk of CIN
Study: NCT02282267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Iressa 250mg oral daily
Study: NCT02285413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: DC vaccination without cisplatinum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination with cisplatinum
Description: DC vaccination with cisplatinum
Study: NCT00130156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bunazosin
Description: Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
Study: NCT02638896

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib (0.4g/d) will be the background therapy.
Study: NCT01769274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
Study: NCT02749292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: re-dosing dependent on interventional arm parameter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: re-dosing dependent on interventional arm parameter.
Study: NCT02638896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib (0.4g/d) will be the background therapy.
Study: NCT00534794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elestat
Description: Elestat BID for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pataday
Description: Pataday QD for 2 days
Study: NCT04325152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FCSEMS plus Clip
Description: After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FCSEMS
Description: FCSEMS was released as the same as mentioned above. No fixating method was used.
Study: NCT02182128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study: NCT01770431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
Study: NCT00512837

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile phone technology
Study: NCT04334655

Intervention type: OTHER
Intervention: Physical Therapy
Description: Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.

Intervention type: OTHER
Intervention: Physical Therapy
Description: Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.

Intervention type: OTHER
Intervention: Physical Therapy
Description: Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.

Intervention type: OTHER
Intervention: Physical Therapy
Description: Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
Study: NCT00839059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days
Study: NCT04513808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol-based total intravenous anesthesia
Description: Propofol-based total intravenous anesthesia, titrated to clinical need.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane intravenous anesthesia
Description: Sevoflurane intravenous anesthesia, titrated to clinical need.
Study: NCT02457338

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Study: NCT02096211

Intervention type: DEVICE
Group type: OTHER
Intervention: COC 36mm
Description: Total Hip Replacement with COC 36mm Acetabular Cup System
Study: NCT04483778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: second generation 4-1BBζ B7H3-EGFRt-DHFR
Description: Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Description: Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Study: NCT01095055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1
Description: Group 1A - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMa1 and MVA AMA1
Description: Group 1B - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly
Study: NCT00130156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartin
Description: After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartin
Description: After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
Study: NCT02273544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation - low)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation - medium)
Study: NCT02638896

Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: Celecoxib (0.4g/d) will be the background therapy.
Study: NCT00377611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Study: NCT01728753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1200 mg TID on Day 1, then 600 mg TID on Days 2-5
Study: NCT02273544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation - high)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER - commercial formulation
Study: NCT03586258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Imaging
Description: Anatomical, diffusion, and/or functional MRI

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain Imaging
Description: Anatomical, diffusion, and/or functional MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation (GVS)
Description: Stimulation versus Sham

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Galvanic Vestibular Stimulation (GVS)
Description: Stimulation versus Sham
Study: NCT01043601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT005
Description: inhaled, twice daily for 1 week duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT005
Description: inhaled, twice daily for 1 week duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: inhaled, twice daily for 1 week duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 µg (Foradil Aerolizer)
Description: inhaled, twice daily for 1 week duration
Study: NCT02616900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSight Eyewear
Description: primary intervention
Study: NCT02076958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Advisor education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Advisor education
Study: NCT03318484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Care
Description: Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Care
Description: Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonodynamic therapy
Description: SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
Study: NCT01028118

Intervention type: OTHER
Group type: OTHER
Intervention: Identifying experience with violence
Description: Asking about life experience with violence and Cognitive Behavior Therapy.
Study: NCT00599716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
Study: NCT05042024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Conventional periodontal therapy, non-surgical periodontal therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Conventional periodontal therapy, non-surgical periodontal therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Conventional periodontal therapy, non-surgical periodontal therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-arginine aspartate administration
Description: The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-ornithine aspartate administration
Description: The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
Study: NCT01122901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01093430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior superior iliac spine
Description: The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.